AI-Based Diagnostic Platform Capabilities With Lyme Disease as a Use Case: Integrative Exploration
Online Journal of Public Health Informatics · 13.07.2026 · 18 · e87529-e87529
DOI: 10.2196/87529 ↗Kurz gefasst
Fachartikel in der Zeitschrift Online Journal of Public Health Informatics, online erschienen am 13.07.2026. Verfasst von Sarah P Maxwell und 5 weiteren Autor:innen. Beteiligte Einrichtung: Public Health, Public Management, and Public Policy, School of Economic, Political and Policy Sciences, The University of Texas at Dallas, 800 W Camb…. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Lyme disease (LD) is the most common vector-borne disease in the United States. It is difficult to diagnose because it can mimic numerous other conditions, and testing protocols may not be sufficient. Although the Centers for Disease Control and Prevention (CDC) recommend a 2-tiered serologic testing approach for LD diagnosis, many patients are diagnosed clinically based on criteria such as the erythema migrans rash and, particularly when the rash is not present, various symptom patterns, exposure history, other information, and clinician observations. Against this backdrop, online symptom checkers, using artificial intelligence (AI) processing techniques, are increasingly used to obtain diagnostic information and resources. With LD as a use case, this research applied a modified capabilities approach to explore the relative effectiveness and utility of AI-based tools in application and comparison to serologically (CDC+) and clinically based diagnoses.
Objective
The overarching goal of this research was to provide a baseline exploration of AI-assisted diagnostic tools relative to more traditional medical assessment approaches in detecting complex infectious diseases. To assess the potential diagnostic utility (DU) of online symptom checker platforms with LD as a use case, this study aimed to (1) evaluate platform performance in identifying LD across different diagnostic cohorts; (2) compare symptom patterns and severity distributions among online LD diagnoses; and (3) identify the most frequently co-occurring conditions potentially misclassified as LD or vice versa.
Methods
Data were drawn from a limited structured survey of patients with confirmed or probable LD, including diagnostic pathways (CDC+ and/or clinical), symptom profiles and severity, treatment history, and time to diagnosis. These patient cases were then entered into 3 leading AI-based symptom checker platforms—MediFind, Isabel, and WebMD—to examine diagnostic performance. Descriptive analytics, logistic regressions, and postestimation analyses were used to identify patterns of DU and interaction effects among cohort type, symptom severity, and AI-based platforms. This survey-based research was not intended to serve as an experiment or clinical trial.
Results
DU varied significantly across platforms and symptom severity thresholds. DU improved at higher symptom severity thresholds (≥3; P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Public Health, Public Management, and Public Policy, School of Economic, Political and Policy Sciences, The University of Texas at Dallas, 800 W Cambell, Richardson, TX, 75080, United States, 1 972-883-6469.
- Schar School of Policy and Government, George Mason University, Fairfax, VA, United States.
- Public and Non-Profit Management, School of Economic, Political and Policy Sciences, The University of Texas at Dallas, Richardson, TX, United States.
- School of Biological Sciences, University of Oklahoma, Norman, OK, United States.
- O'Donnell School of Public Health, The University of Texas Southwestern Medical Center, Dallas, TX, United States.
- Laboratory for Human Neurobiology, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, United States.
Zitieren
APA
Maxwell, S. P., McNeely, C. L., Zeraatpisheh, A., Brooks, C., Maxwell, C., & Thomas, K. C. (2026). AI-Based Diagnostic Platform Capabilities With Lyme Disease as a Use Case: Integrative Exploration. Online Journal of Public Health Informatics, 18, e87529-e87529. https://doi.org/10.2196/87529
Vancouver
Maxwell SP, McNeely CL, Zeraatpisheh A, Brooks C, Maxwell C, Thomas KC. AI-Based Diagnostic Platform Capabilities With Lyme Disease as a Use Case: Integrative Exploration. Online Journal of Public Health Informatics. 2026;18:e87529-e87529. doi:10.2196/87529
BibTeX
@article{Maxwell2026,
author = {Maxwell, Sarah P and McNeely, Connie L and Zeraatpisheh, Abdollah and Brooks, Chris and Maxwell, Claire and Thomas, Kevin C},
title = {AI-Based Diagnostic Platform Capabilities With Lyme Disease as a Use Case: Integrative Exploration},
journal = {Online Journal of Public Health Informatics},
year = {2026},
volume = {18},
pages = {e87529--e87529},
doi = {10.2196/87529}
}
EUVIMED